Abstract
Iodine has strong antimicrobial properties and has been used in topical applications as antiseptic. Its systemic use in form of iodine complexes derived from dried seaweed extract is beneficial in treating various disorders. Hepatitis C Virus (HCV) chronic infection is present in 6-10% of the Pakistani population and is a major healthcare burden that could benefit from innovative therapeutic regimens.
Objective A pilot study has shown the safety and efficacy of iodine complexes in chronic Hepatitis C virus infection. and this clinical study is aimed to further explore the previous findings.
Methods This is an open-labeled, active-controlled, three-arm, parallel-group study including 90 patients of chronic HCV infection with each arm having 30 patients. The patient groups received 15mg/day iodine complex only, the standard of care therapy interferon+ribavirin, and iodine complex in combination with interferon+ribavirin regimen for 6 months. Efficacy assessment will base upon post-treatment Rapid Virological Response (RVR) at 4 weeks, Early Virological Response (EVR) at 12 weeks, and End of Treatment Viral Response (ETR) at 24/48 weeks.
Results As only 3.33% of patients showed at the ETR with iodine complex alone, combination with interferon+ribavirin showed significant improvement in comparison to interferon+ribavirin alone. Iodine complex+ interferon+ribavirin showed 80% RVR and 90% ETR while the standard of care therapy showed 66.7% RVR and 76.67% ETR, respectively. No additional adverse events of iodine complex were observed.
Conclusion Iodine complex showed a significant synergistic effect when combined interferon+ribavirin regimen and could be useful in relapsers and non-responders.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01463592
Funding Statement
The study was funded by MTI Medical, Pakistan;
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was IRB approved from Post Graduate Medical Institute, Lahore.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We have all data available. Will include more data if required.
